贝伐单抗在结直肠癌的应用护理

Nursing Care of Patients With Colorectal Cancer Treated With Bevacizumab

目的分析贝伐单抗在结直肠癌的应用中不良反应发生情况,总结护理对策。方法 2015年1月—2017年1月,医院采用贝伐单抗治疗结直肠癌84例。将发生不良反应的对象纳入不良反应组,其余对象纳入对照组。结果不良反应发生率22.62%,心血管系统14例、血液系统3例、消化系统2例、蛋白尿1例、伤口疼痛1例,部分有多种不良反应。不良反应组总剂量、合并基础疾病种数高于对照组,差异有统计学意义(P<0.05)。结论贝伐单抗不良反应发生风险较高,需要重视不良反应的护理。

Objective To analyze the incidence of adverse reactions of bevacizumab in colorectal cancer, and summarize the nursing countermeasures. Methods From January 2015 to January 2017, 84 patients with colorectal cancer were treated with bevacizumab in our hospital. The adverse reactions were included in the adverse reaction group, and the other subjects were included in the control group. Results The incidence of adverse reactions was 22.62%. There were 14 cases of cardiovascular system, 3 cases of blood system, 2 cases of digestive system, 1 cases of proteinuria, 1 cases of wound pain, and some of them had many adverse reactions. The total dose of adverse reaction group and the number of basic diseases were higher than those of the control group, the difference was statistically signifcant （P 〈 0.05）. Conclusion The risk of adverse reactions in bevacizumab is high, and attention should be paid to the care of adverse reactions. [